Rarified Biosciences Inc. has reported mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer, graft-vs.-host disease, systemic lupus erythematosus, scleroderma, psoriatic arthritis, primary sclerosing cholangitis, rheumatoid arthritis and inflammatory bowel disease.